Endometriosis Management: Workflow on Genomics and Proteomics and Future Biomolecular Pharmacotherapy
Abstract:Background: Endometriosis is an estrogen-dependent disease, associated with pelvic pain and infertility, with still limited knowledge of the pathogenesis, pathophysiology of related infertility and evolution.
Objective: To investigate proteogenomic approaches and new trends of endometriosis treatment.
Methods: A literature search was carried out for all articles on endometriosis related to immune system, and to nonhormonal, antiangiogenic and experimental therapies.
Results/Conclusions: Classic endometriosis pharmacotherapy is represented by GnRH agonists, oral contraceptives and Type II progesterone receptor ligands. New proteomic and genomic technologies could help to clarify the aetiology of endometriosis and promise the rapid identification of a new generation of drugs with a specific molecular target, with the aim to ameliorate the patients' quality of life.
Document Type: Research Article
Affiliations: Department of Obstetrics and Gynecology, “Vito Fazzi” Hospital, Lecce, Italy.
Publication date: September 1, 2008
More about this publication?
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.